September's top stories are here: Is biotech back? Explore encouraging signs and more

Take advantage of 25% off an annual STAT+ subscription to dive into these stories.

My Account    STAT+ Check out September's top stories. If you like what you see, join the STAT+ community today – and enjoy 25% off your first year with code LOYAL25. Molly Ferguson/STAT 1   Is biotech back? Don't jinx it, but the signs are encouraging By Adam Feuerstein Win McNamee/Getty Images 2   After lagging far behind, NIH now seems on pace to spend its entire $47 billion budget by Sept. 30 By Megan Molteni, Anil Oza, and J. Emory Parker Natsumi Chikayasu for STAT 3   Hospitals get dinged for reporting too many infections. In some cases, the solution is not to test By Tara Bannow 25% off STAT+ Get 25% off your first year of STAT+ with discount code LOYAL25. SUBSCRIBE NOW More Top Stories 4   Uniqure and its Huntington's therapy win the week in biotech By Adam Feuerstein 5   RFK Jr. ally's 'smoking gun' study on vaccines and chronic illness is fundamentally flawed By Jake Scott 6   What the evidence tells us about Tylenol, leucovorin, and autism By Matthew Herper 7   Surgeon general nominee Casey Means discloses financial ties to supplement industry By Sarah Todd and Isabella Cueto 8   House bill cuts HHS budget but excludes RFK Jr.'s reorganization, maintains NIH funding By John Wilkerson and Jonathan Wosen 9   From an elixir for 'little hotheads' to deadly overdoses, how Tylenol became a medicinal scapegoat By Megan Molteni 10   Winner of mRNA Nobel Prize says ACIP member's claim that Covid vaccines persist is 'absolutely impossible' By Matthew Herper read more STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails Update Newsletter Preferences • Contact Us • Advertise with Us